RLY-4008 is a small molecule commercialized by Relay Therapeutics, with a leading Phase II program in Bile Duct Cancer (Cholangiocarcinoma). According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of RLY-4008’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for RLY-4008 is expected to reach an annual total of $29 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

RLY-4008 Overview

RLY-4008 is under development for the treatment of metastatic solid tumors like intrahepatic cholangiocarcinoma and breast cancer. It is administered by oral route. The drug candidate acts by targeting fibroblast growth factor receptor 2 (FGFR2). It is being developed based on Dynamo platform.

It was under development for the treatment of gastric cancer, endometrial cancer.

Relay Therapeutics Overview

Relay Therapeutics is a biotechnology company that develops therapies for multiple diseases. The company’s technology enables the rational allosteric drug discovery process to design better drugs. It leverages insights from protein motion to develop its products. Relay Therapeutics brings together scientific advances including biophysics, chemistry, structural biology, computation, and biology to enable new approaches for therapeutic intervention in disease. Its research focuses on the discovery and development of oncology therapeutics. The company partners with various healthcare companies. Relay Therapeutics is headquartered in Cambridge, Massachusetts, the US.

The company reported revenues of (US Dollars) US$3 million for the fiscal year ended December 2021 (FY2021), a decrease of 96.3% over FY2020. The operating loss of the company was US$364.7 million in FY2021, compared to an operating loss of US$55.8 million in FY2020. The net loss of the company was US$363.9 million in FY2021, compared to a net loss of US$52.4 million in FY2020. The company reported revenues of US$0.3 million for the third quarter ended September 2022, a decrease of 5.8% over the previous quarter.

For a complete picture of RLY-4008’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.